Drug Topics January 24, 2026
GLP-1 therapies gain popularity, but patient adherence struggles due to fragmented support and emotional barriers.
Few drug categories have expanded as quickly or as visibly as glucagon-like peptide-1 (GLP-1) therapies. Nearly 1 in 5 US adults now report having taken a GLP-1, and consumer adoption of weight-loss injectables has more than doubled in less than 2 years.1,2 As pricing pressure eases and competition increases, analysts expect utilization to continue rising across both diabetes and weight-management indications.
The arrival of oral GLP-1 options marks the next inflection point. A daily pill, available at retail pharmacies, removes one of the most commonly cited barriers to initiation: injections.3 For many patients, the oral dosage form alone makes treatment feel more approachable.
But easier...
Today's Sponsors
Today's Sponsor